Skip to main content
Clinical Trials/NCT04053361
NCT04053361
Completed
Not Applicable

Catheter Ablation of Atrial Fibrillation/Tachycardia in Patients With Pulmonary Hypertension: a Randomised Study

General University Hospital, Prague3 sites in 1 country76 target enrollmentMay 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
General University Hospital, Prague
Enrollment
76
Locations
3
Primary Endpoint
Arrhythmia recurrence
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Atrial fibrillation (AF) and atrial tachycardia (AT), including type I atrial flutter, are frequently observed in patients with pulmonary hypertension (PH). Catheter ablation of AF / AT has been established as an effective treatment option in selected patients. However, little is known about the efficacy and safety of this approach in patients with PH. It has also been shown that considerable proportion of patients with PH after acutely successful catheter ablation suffer from the recurrence of clinical or newly manifested arrhythmia. We propose a prospective study to compare two ablation strategies in a randomized fashion: radiofrequency catheter ablation targeting only the clinical arrhythmia versus more extensive substrate-based catheter ablation. This project will investigate the clinical outcome of patients with pulmonary hypertension and symptomatic atrial fibrillation / tachycardia who will be randomly allocated to selective versus complex radiofrequency catheter ablation of arrhythmogenic substrate.

Registry
clinicaltrials.gov
Start Date
May 1, 2018
End Date
December 31, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
General University Hospital, Prague
Responsible Party
Principal Investigator
Principal Investigator

Stepan Havranek

Consultant

General University Hospital, Prague

Eligibility Criteria

Inclusion Criteria

  • Pre-capillary PH (PAMP ≥25 mmHg; PAWP ≤15 mmHg) or combined post- a pre-capillary PH (PAMP ≥25 mmHg; PAWP \>15 mmHg; DPG ≥7 mmHg and/or PVR \>3 W.u.) of any etiology.

Exclusion Criteria

  • Complex congenital heart defects (corrected or uncorrected)
  • Isolated post-capillary PH (PAMP ≥25 mmHg; PAWP \>15 mmHg; DPG \<7 mmHg and/or PVR ≤ 3W.u.)
  • Previous catheter ablation for AF / AT / AFL
  • Previous or scheduled cardiac surgery-
  • NYHA Class IV, cardiogenic shock
  • Life expectancy \<1 year
  • Non-compliance

Outcomes

Primary Outcomes

Arrhythmia recurrence

Time Frame: 3 months

Documented arrhythmia recurrence \>30 s without antiarrhythmic drugs in post-blanking period after the index ablation

Secondary Outcomes

  • On-drugs arrhythmia recurrence(3 months)
  • Symptoms of arrhythmia(3 months)
  • Change in Quality of life(6 months)
  • Mortality(3 months)
  • Reablation(3 months)
  • Procedure-related complication rate(1 day (Once))

Study Sites (3)

Loading locations...

Similar Trials